12 results
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
25 May 23
Regulation FD Disclosure
5:10pm
) in 1 tamibarotene 2,3 AML patients 33% Chronic daily dosing of tamibarotene as a single-agent and in combination with azacitidine has been CR 50
8-K
EX-2.1
SYRS
Syros Pharmaceuticals Inc.
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
varieties of the same disease, disorder or condition (e.g., acute vs. chronic) shall not be treated as separate Indications, (2) the treatment
10-K
qh6z v36udow
20 Mar 17
Annual report
12:00am
- Prev
- 1
- Next